Buscar
Repligen Corp
RGENAñadir a la lista de seguimiento
136.060USD
-0.940-0.69%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
7.66BCap. mercado
148.95P/E TTM
Más Datos de Repligen Corp Compañía
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Información de Repligen Corp
Símbolo de cotizaciónRGEN
Nombre de la empresaRepligen Corp
Fecha de salida a bolsaApr 29, 1986
Director ejecutivoLoeillot (Olivier)
Número de empleados1778
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 29
DirecciónBuilding 1, Suite 100
CiudadWALTHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02453
Teléfono17814499560
Sitio Webhttps://www.repligen.com/
Símbolo de cotizaciónRGEN
Fecha de salida a bolsaApr 29, 1986
Director ejecutivoLoeillot (Olivier)
Ejecutivos de Repligen Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
Independent Director
Independent Director
--
--
Mr. James R. Bylund
Mr. James R. Bylund
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Repligen Corp?
Los cinco principales accionistas de Repligen Corp son: Ms. Karen A. Dawes
¿Cuántas instituciones poseen acciones de Repligen Corp (RGEN)?
A fecha de 2026Q1, 1067 instituciones poseen acciones de Repligen Corp, con un valor de mercado combinado de aproximadamente 65.93M, lo que representa el 116.89% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2643397.00.
¿Cuál es la mayor fuente de ganancias de Repligen Corp?
El 2026Q1, el segmento empresarial Product revenue - Filtration products generó la ganancia más alta para Repligen Corp, ascendiendo a 402.79M y representando el 54.58% de la ganancia total.
